UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1330-6
Program Prior Authorization/Notification
Medication Dojolvi® (triheptanoin)
P&T Approval Date 10/2020, 10/2021, 10/2022, 10/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Dojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and
fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-
chain fatty acid oxidation disorders (LC-FAOD).
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Dojolvi will be approved based on ALL of the following criteria:
a. Diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD)
- AND -
b. Disease has been molecularly confirmed (i.e., genetic testing)
- AND -
c. Patient is not receiving Dojolvi in combination with any other medium-chain
triglyceride (MCT) products
Authorization will be issued for 12 months.
B. Reauthorization
1. Dojolvi will be approved based on all the following criteria:
a. Documentation of positive clinical response to Dojolvi therapy
- AND -
b. Patient is not receiving Dojolvi in combination with any other medium-chain
triglyceride (MCT) products
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
© 2025 UnitedHealthcare Services, Inc.
1
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits and/or Medical Necessity may be in place.
4. References:
1. Dojolvi [package insert]. Novato, CA: Ultragenyx Pharmaceutical, Inc.; October 2023.
Program Prior Authorization/Notification - Dojolvi® ( triheptanoin )
Change Control
10/2020 New program
10/2021 Annual review with no change to clinical coverage criteria. Updated
reference.
10/2022 Annual review with no change to clinical coverage criteria. Updated
reference. Added state mandate footnote.
10/2023 Annual review with no change to clinical coverage criteria.
5/2024 Revised initial authorization to 12 months. Updated reference.
5/2025 Annual review with no change to clinical coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2